© 2000 American Heart Association, Inc.
Integrative Physiology |
Endothelin Receptor Antagonism Ameliorates Mast Cell Infiltration, Vascular Hypertrophy, and Epidermal Growth Factor Expression in Experimental Diabetes
From the University of Melbourne, Department of Medicine, Austin and Repatriation Medical Centre, Heidelberg, Victoria, Australia.
Correspondence to Dr Richard E. Gilbert, Department of Medicine, Austin & Repatriation Medical Centre (Repat Campus), Banksia Street, West Heidelberg, Victoria 3081, Australia. E-mail gilbert{at}austin.unimelb.edu.au
Abstract—Vascular hypertrophy, a feature of experimental and human diabetes, has been implicated in the pathogenesis of the microvascular and macrovascular complications of the disease. In the present study, we sought to examine the role of endogenous endothelin and its relation to vascular growth factors in the mediation of vascular hypertrophy in experimental diabetes and to examine the contribution of mast cells to this process. Vessel morphology, endothelin, growth factor gene expression, and matrix deposition were studied in the mesenteric arteries of control and streptozotocin-induced diabetic Sprague-Dawley rats treated with or without the dual endothelinA/B receptor antagonist bosentan (100 mg · kg-1 · d-1) during a 3-week period. Compared with control animals, diabetic animals had significant increases in vessel weight, wall-to-lumen ratio, mast cell infiltration, extracellular matrix deposition, and gene expression of epidermal growth factor (EGF) and transforming growth factor-ß1. In diabetic, but not control, vessels, not only were EGF mRNA and endothelin present in endothelial cells, but also their expression was observed in adventitial mast cells. Immunoreactive endothelin was present in the media of mesenteric vessels of diabetic, but not control, animals. Bosentan treatment significantly reduced mesenteric weight, wall-to-lumen ratio, mast cell infiltration, matrix deposition, and EGF mRNA but did not prevent the overexpression of transforming growth factor-ß1 mRNA in diabetic rats. These findings suggest that endogenous endothelin and EGF may play a role in diabetes-induced vascular hypertrophy and that mast cells may be pathogenetically involved in this process.
Key Words: endothelin • mast cell • growth factor • vasculature • diabetes
This article has been cited by other articles:
 |
|
 |
|
  D. B. Murray, J. D. Gardner, G. L. Brower, and J. S. Janicki Effects of nonselective endothelin-1 receptor antagonism on cardiac mast cell-mediated ventricular remodeling in rats Am J Physiol Heart Circ Physiol, March 1, 2008; 294(3): H1251 - H1257. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Sachidanandam, V. Portik-Dobos, A. K. Harris, J. R. Hutchinson, E. Muller, M. H. Johnson, and A. Ergul Evidence for Vasculoprotective Effects of ETB Receptors in Resistance Artery Remodeling in Diabetes Diabetes, November 1, 2007; 56(11): 2753 - 2758. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. G. Trentin, M. B. Fernandes, P. D'Orleans-Juste, and G. A. Rae Endothelin-1 causes pruritus in mice. Experimental Biology and Medicine, June 1, 2006; 231(6): 1146 - 1151. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. K. Harris, J. R. Hutchinson, K. Sachidanandam, M. H. Johnson, A. M. Dorrance, D. W. Stepp, S. C. Fagan, and A. Ergul Type 2 Diabetes Causes Remodeling of Cerebrovasculature via Differential Regulation of Matrix Metalloproteinases and Collagen Synthesis: Role of Endothelin-1 Diabetes, September 1, 2005; 54(9): 2638 - 2644. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Guo, W. Su, S. Allen, H. Pang, A. Daugherty, E. Smart, and M. C. Gong COX-2 Up-regulation and vascular smooth muscle contractile hyperreactivity in spontaneous diabetic db/db mice Cardiovasc Res, September 1, 2005; 67(4): 723 - 735. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Sato, K. Harada, K. Kizawa, T. Sanzen, S. Furubo, M. Yasoshima, S. Ozaki, M. Ishibashi, and Y. Nakanuma Activation of the MEK5/ERK5 Cascade Is Responsible for Biliary Dysgenesis in a Rat Model of Caroli's Disease Am. J. Pathol., January 1, 2005; 166(1): 49 - 60. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Kelly, A. J. Cox, R. M. Gow, Y. Zhang, B. E. Kemp, and R. E. Gilbert Platelet-Derived Growth Factor Receptor Transactivation Mediates the Trophic Effects of Angiotensin II In Vivo Hypertension, August 1, 2004; 44(2): 195 - 202. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. R. Orth, G. Odoni, H. Karkoszka, H. Ogata, C. Viedt, K. Amann, P. Ferrari, and E. Ritz Combination treatment with an ETA-receptor blocker and an ACE inhibitor is not superior to the respective monotherapies in attenuating chronic transplant vasculopathy in different aorta allotransplantation rat models Nephrol. Dial. Transplant., January 1, 2003; 18(1): 62 - 69. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Kelly, P. Aaltonen, A. J. Cox, J. R. Rumble, R. Langham, S. Panagiotopoulos, G. Jerums, H. Holthofer, and R. E. Gilbert Expression of the slit-diaphragm protein, nephrin, in experimental diabetic nephropathy: differing effects of anti-proteinuric therapies Nephrol. Dial. Transplant., July 1, 2002; 17(7): 1327 - 1332. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Jandeleit-Dahm, K. M. Hannan, C. A. Farrelly, T. J. Allen, J. R. Rumble, R. E. Gilbert, M. E. Cooper, and P. J. Little Diabetes-Induced Vascular Hypertrophy Is Accompanied by Activation of Na+-H+ Exchange and Prevented by Na+-H+ Exchange Inhibition Circ. Res., December 8, 2000; 87(12): 1133 - 1140. [Abstract] [Full Text] [PDF]
|
|